Crossmark

Pre-eclampsia: pathogenesis, novel diagnostics and therapies

Crossref DOI link: https://doi.org/10.1038/s41581-019-0119-6

Published Online: 2019-02-21

Published Print: 2019-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Phipps, Elizabeth A.

Thadhani, Ravi

Benzing, Thomas

Karumanchi, S. Ananth https://orcid.org/0000-0002-2281-6831
License Information

Text and Data Mining valid from 2019-02-21
More Information

Article History

First Online: 21 February 2019

Change Date: 8 May 2019

Change Type: Correction

Change Details: In the version of this article originally published online, the date when Francois Mauriceau published one of the earliest descriptions of pre-eclampsia was incorrectly stated to be 1637, which is actually his year of birth. The work was published in 1668. This error has been corrected in the PDF and HTML versions of the article.

Competing interests

: S.A.K. is co-inventor on multiple patents (US Patent and Trademark Office (USPTO) #7,740,849, #7,407,658, #7,335,362, #7,344,892 and #8969322B2) related to the use of angiogenic markers for the diagnosis, prediction and therapy of pre-eclampsia. R.T. is a co-inventor on a patent (USPTO #7,344,892) related to the use of angiogenic proteins for the prediction of pre-eclampsia. These patents are held at Harvard Hospitals (Beth Israel Deaconess Medical Center and Massachusetts General Hospital). S.A.K and R.T. have financial interests in Aggamin Therapeutics LLC and have previously served as consultants for Roche Diagnostics and ThermoFisher. S.A.K. has received a research grant from Siemens. R.T. and T.B. have received a research grant from Kaneka Pharmaceuticals. The other authors report no competing interests.